Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis

  title={Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis},
  author={Charlotte E. Teunissen and Ellen Iacobaeus and Mohsen Khademi and Lou Brundin and Niklas Norgren and M.J.A. Koel-Simmelink and Marc Schepens and Femke H Bouwman and Harry A. M. Twaalfhoven and Henk J Blom and C. Jakobs and Christine D. Dijkstra},
  pages={1322 - 1329}
Objective: Axonal degeneration is the likely cause of disease progression in multiple sclerosis (MS). Our previous results indicated that neuron-specific N-acetylaspartate (NAA) is a candidate CSF biomarker for disease progression in MS. The aim of this study was to explore the potential of NAA as an early biomarker of axonal damage in MS. Next, we wanted to know the additional value of measurement of NAA compared to other candidate markers for axonal damage, such as neurofilament subunits and… 

Figures from this paper

CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome

The association of NFH levels with brain volume but not lesion volume changes supports the association of these markers with axonal damage, and results confirm increased neurofilament levels already in CIS being related to the level of physical disability.

N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis

The data suggest that PP and SPMS likely share similar mechanisms of axonal damage, and Nf heavy can be a biomarker of ongoing axonal Damage suggesting it as a good tool for possible treatment monitoring in the progressive MS forms.

Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis

Evaluated CSF levels of neurofilament heavy chain protein (NfHSMI35) are likely to provide a useful surrogate for measuring the rate of neurodegeneration in MS, and their dissociation with biomarkers of inflammation suggests that the mechanisms responsible for their production are at least partly independent.

CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration

It is concluded that CSF-NFL may mirror the proposed slow axonal degeneration in PPMS, but does not reflect the disease severity.

Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients

Repeated sampling of a subset of MS cases showed that pNF-H levels can fluctuate over time, likely reflecting temporal dynamics of axonal injury in MS.

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis

Serum and CSF NfL concentrations were associated with long-term clinical outcomes in MS patients and are promising biomarkers for disease severity stratification supporting treatment decisions.

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis

GFAP, a marker for astrogliosis, is a potential biomarker for MS progression and may have a role in clinical trials for assessing the impact of therapies on MS progression.

Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica

Determination of serum and CSF NAA levels may represent a suitable tool in the diagnostic laboratory workup to differentiate multiple sclerosis and NMO.



N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry

CSF NAA concentration in MS patients is related to clinical performance and MRI measures of disease burden and may therefore be an important neuron specific marker of disease severity and possibly progression.

Neurofilament and glial fibrillary acidic protein in multiple sclerosis

CSF levels of neurofilament light and glial fibrillary acidic protein may have prognostic value in multiple sclerosis and correlated with progression in patients with an active relapse and in clinically stable patients.

Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis

This study showed similar CSF tau concentrations in MS patients with different clinical characteristics, suggesting that tau protein does not seem to be a useful routine clinical marker of axonal damage.

Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis

Predicting conversion from CIS to MS can be improved if CSF markers are combined with MRI, and Tau and NfHSMI35 are valuable biomarkers for axonal damage in the CIS patients.

Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis

No significant difference among different subtypes of MS could be detected, although highest levels were found in very early disease stages and a tendency towards higher CSF tau levels in patients with pronounced intrathecal IgG synthesis is supported, supporting the notion that axonal damage is influenced by inflammatory activity.

I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy

Over a three-year period, treatment with IFN β-1a significantly slowed the progression of whole-brain and GM atrophy, and of T1-hypointense LV accumulation, when compared with the control group.

Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability.

Cerebral axonal damage begins and contributes to disability from the earliest stages of the disease, even before significant disability (measured using the Expanded Disability Status Scale [EDSS]) was evident clinically.

The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers

The new Global Multiple Sclerosis Severity Scale may provide a statistically powerful tool for comparing overall disease severity and be useful for validating the biomarker concept in MS.